Jonakayem Pharma - Formulation Opc Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 9 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -5.84%
(FY 2021)
- Profit -222.74%
(FY 2021)
- Ebitda -1236.28%
(FY 2021)
- Net Worth -4614.68%
(FY 2021)
- Total Assets 59.80%
(FY 2021)
About Jonakayem Pharma - Formulation Opc
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Jonakayem Pharma - Formulation Opc Private Limited India is Navneet Verma as CEO. Navneet Verma serves as a director at the Company.
- CIN/LLPIN
U24110MH2015OPC261725
- Company No.
261725
- Incorporation Date
10 Feb 2015
- Date of AGM
25 Sep 2018
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Jonakayem Pharma - Formulation Opc Private Limited offer?
Jonakayem Pharma - Formulation Opc Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at Jonakayem Pharma - Formulation Opc?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Navneet Verma | CEO | 24-Dec-2020 | Current |
Board Members(0)
| Name | Designation | Appointment Date | Status |
|---|
Financial Performance of Jonakayem Pharma - Formulation Opc.
Jonakayem Pharma - Formulation Opc Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 5.84% decrease. The company also saw a substantial fall in profitability, with a 222.74% decrease in profit. The company's net worth observed a substantial decline by a decrease of 4614.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jonakayem Pharma - Formulation Opc?
In 2018, Jonakayem Pharma - Formulation Opc had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jonakayem Pharma - Formulation Opc?
Unlock and access historical data on people associated with Jonakayem Pharma - Formulation Opc, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jonakayem Pharma - Formulation Opc, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jonakayem Pharma - Formulation Opc's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
